New vaccine strategy aims to shield lymphoma patients from deadly pneumonia
NCT ID NCT04214444
First seen Feb 20, 2026 · Last updated May 06, 2026 · Updated 10 times
Summary
This study tested a two-step pneumococcal vaccine in 26 people with diffuse large B-cell lymphoma who were receiving rituximab chemotherapy. The goal was to see if giving two different pneumonia vaccines in sequence could boost protection against serious infections. Researchers measured immune response after treatment to determine how well the strategy worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GYAN
Tours, 37044, France
Conditions
Explore the condition pages connected to this study.